SUSAR stands for Suspected Unexpected Serious Adverse Reaction. It refers to an adverse event that occurs during a clinical trial which is both serious and unexpected, and is suspected to be related to the study drug or intervention.
SUSARs are a critical component of drug safety monitoring in clinical research. They require prompt reporting to regulatory authorities and ethics committees, as they may impact the overall safety profile of the investigational product and the conduct of the clinical trial.
SUSARs play a crucial role in ensuring patient safety and maintaining the integrity of clinical trials. They serve as early warning signals for potential serious risks associated with investigational products, allowing researchers and regulatory bodies to take swift action to protect study participants and reassess the risk-benefit profile of the study.
The identification and reporting of SUSARs are essential for compliance with regulatory requirements and ethical standards in clinical research. Proper management of SUSARs contributes to the overall quality and reliability of clinical trial data, ultimately influencing decisions about drug development, approval, and post-marketing surveillance.
A recent publication in npj Digital Medicine explored the use of AI-generated radiology reports — and the results are worth…
The Axcellant team recently traveled to New York to meet with research partners and clinical collaborators from across the U.S.…
What Are Nuclear Medicine Procedures and How Are They Used in Clinical Trials? Nuclear medicine procedures (NMPs) are diagnostic and/or…
Copyright @ 2025 Axcellant